Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Trial Results of IMMU-132
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
Aditya Bardia, MD, MPH, on Triple-Negative Breast Cancer: Trial Results of IMMU-132
Posted: Thursday, December 7, 2017
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, discusses the efficacy of sacituzumab govitecan (IMMU-132), an anti–Trop-2-SN-38 antibody-drug conjugate, as ≥ 3rd-line therapeutic option for patients with relapsed/refractory metastatic triple-negative breast cancer.
